Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pyxis Oncology, Inc. - Common Stock
(NQ:
PYXS
)
1.600
-0.070 (-4.19%)
Streaming Delayed Price
Updated: 1:00 PM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pyxis Oncology, Inc. - Common Stock
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
December 19, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
November 20, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
November 12, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
November 11, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
August 29, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
August 14, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
July 29, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
June 10, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 30, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
May 14, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
May 09, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
March 27, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
March 21, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
March 13, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
March 07, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
March 05, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Announces $50 Million Private Placement
February 27, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 29, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
November 28, 2023
Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology modalities
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
November 07, 2023
From
Pyxis Oncology
Via
GlobeNewswire
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
October 13, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
NASDAQ:PYXS Investor Notice: Investigation over Possible Securities Laws Violations by Pyxis Oncology, Inc.
October 05, 2023
San Diego, CA -- (SBWIRE) -- 10/05/2023 -- Pyxis Oncology, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
September 27, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
August 31, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Successfully Completes Acquisition of Apexigen
August 23, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
August 11, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
August 01, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.